CClinicalTrials.gg
CompletedNCT03362216Updated Dec 8, 2017

Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment

An interventional study of Compound Methyl Salicylate Liniment and Diclofenac Sodium Liniment in Soft Tissue Injuries, sponsored by Peking University People's Hospital. Completed. Per ClinicalTrials.gov, last updated 2017-12-08.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Sex
All
01

Study summary

This clinical trial program was established according to the ethical principles of the Helsinki declaration and the GCP guiding principle, and a randomized grouping method was used to evaluate the efficacy and safety of Compound Methyl Salicylate Liniment in the treatment of acute and chronic soft tissue pain with a positive control drug, named Diclofenac Sodium Liniment.

Read the detailed description

This study is a randomized, double-blind, parallel controlled multicenter clinical trial for evaluate the efficacy and safety of Compound Methyl Salicylate Liniment in the treatment of acute and chronic soft tissue pain with a positive control drug, named Diclofenac Sodium Liniment. A total of 216 participants with acute or chronic tissue pain participated in this clinical trial. The clinical trial cases were equally allocated to each research center, and each center had 30-35 cases. The proportion of patients with acute soft tissue pain and chronic soft tissue pain was 1:1, and the proportion of the experimental group and the control group was 1:1.The observation index include self pain scale record, tenderness scale and swelling, the evaluation period was 7 days.

The statistical analysis plan is prepared by the unit responsible for the statistics, and is prepared before the formal analysis of the data, and is discussed and identified at the blind audit meeting with the major researchers. Statistical analysis will use SAS8.2 statistical analysis software for data processing, and other statistical analysis plan to make detailed provisions. All the statistical tests were two-sided, and the value of P was less than or equal to 0.05, which would be considered statistically significant. Measurement data use case number, mean, standard deviation, minimum, maximum, median and four sub spacing description, counting data and grade data use case number, percentage description.

02

Conditions studied

  • Soft Tissue Injuries

Browse trials for

Keywords

  • soft tissue, pain
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with various causes of acute and chronic soft tissue
  • Local symptoms and signs include pain, swelling, bruising, tenderness, joint dysfunction; X-ray showed no fracture, dislocation, bone tumors and bone metabolism and open injury.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not belong to the scope of drug use
  • Muscle, tendon, ligament and other soft tissue have broken completely
  • Accompanied by skin damage or fracture, joint dislocation, bone tumor and metabolic bone disease local tissue damage
  • Use of other drugs or therapies for the treatment of acute and chronic soft tissue pain after trauma
  • Difficult to evaluate the effectiveness and safety of new drugs
  • Severe hypertension, severe heart and lung dysfunction, severe arrhythmia, liver, kidney, hematopoietic system and other serious primary diseases, mental patients
  • Pregnant women, lactating women
  • Allergic constitution and allergic to the known components of the drug
  • Participated in other clinical trials in the past month
  • Use similar analgesics within a week
  • Other researchers considered inappropriate patients to participate in the trial
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    experimental group

    Treated with Compound Methyl Salicylate Liniment group

    Drug: Compound Methyl Salicylate Liniment

  • Active comparator
    Control group

    Treated with Diclofenac Sodium Liniment group

    Drug: Diclofenac Sodium Liniment

Interventions

  • DrugCompound Methyl Salicylate Liniment

    Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days

  • DrugDiclofenac Sodium Liniment

    Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days

05

What researchers measure

Primary outcomes

  1. Main observation index

    Self pain scale record (VAS). A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.Operationally a VAS is usually a horizontal line, 100 mm in length, anchored by word descriptors at each end, the patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks, the amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain.

    Time frame: 7 days

Secondary outcomes

  1. Secondary observation index

    Record of tenderness scale(VAS), Swelling. A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. Operationally a VAS is usually a horizontal line, 100 mm in length, anchored by word descriptors at each end, the patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks, the amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain.

    Time frame: 7 days

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03362216
Lead sponsor
Peking University People's Hospital
Responsible party
baoguojiang (Dean of Peking University People's Hospital, Director of department of orthopaedic surgery of Peking University, Chairman of China trauma rescue&treatment association, Peking University People's Hospital) — Principal investigator
First posted
Dec 5, 2017
Start date
Apr 7, 2009
Primary completion
May 22, 2009
Completion
Jun 12, 2009
Last update
Dec 8, 2017

Study contacts

People's Hospital Peking University
study director · Peking University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion